3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
28
Other hematologic neoplasm
20
Plasma cell
17
Sarcoma
16
Myeloid
13
Classical hematology
9
Dermatologic
8
CNS
3
Other neoplasm
2
Genitourinary
2
Breast
2
Gynecologic
1
Gastrointestinal
1
Conditions
Neoplasm Metastasis
9
Colorectal Neoplasms
8
Rectal Neoplasms
7
Liver Neoplasms
7
Carcinoma, Hepatocellular
7
Colonic Neoplasms
6
Rhabdomyosarcoma
4
Hepatoblastoma
4
Wilms Tumor
3
Sarcoma, Ewing
3
Sarcoma
3
Rhabdoid Tumor
3
Retinoblastoma
3
Neuroblastoma
3
Melanoma
3
Medulloblastoma
3
Central Nervous System Neoplasms
3
Carcinoma, Renal Cell
3
Uveal Melanoma
2
Pancreatic Neoplasms
2
Neoplasms, Germ Cell and Embryonal
2
Neoplasms
2
Kidney Neoplasms
2
Hyperthermia
2
Carcinoma, Islet Cell
2
Brain Neoplasms
2
Astrocytoma
2
Appendiceal Neoplasms
2
Vipoma
1
Testicular Neoplasms
1
Interventions
Oxaliplatin
10
Gemcitabine
8
Cisplatin
7
Hepatectomy
6
Fluorouracil
6
Radiofrequency Ablation
5
Liver Transplantation
5
Irinotecan
5
Capecitabine
5
lenvatinib
4
Paclitaxel
4
Neoadjuvant Therapy
4
Folfox protocol
4
Cetuximab
4
Aspirin
4
tislelizumab
3
Surgical Procedures, Operative
3
Nivolumab
3
Carboplatin
3
titanium silicide
2
durvalumab
2
apatinib
2
Trastuzumab
2
S 1 (combination)
2
Leucovorin
2
Lamivudine
2
Introns
2
Ethiodized Oil
2
Drug Therapy
2
DNA, Mitochondrial
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
Melphalan
×
Gastrointestinal
×
Clear all
NCT04150042
2026-01-29
SHARON
General Oncology, Inc.
Phase 1
Recruiting
24 enrolled